Journal
CURRENT BIOLOGY
Volume 15, Issue 21, Pages 1961-1967Publisher
CELL PRESS
DOI: 10.1016/j.cub.2005.09.043
Keywords
-
Categories
Funding
- NINDS NIH HHS [R01 NS38480] Funding Source: Medline
Ask authors/readers for more resources
Neurofibromatosis Type 1 (NF1) is a common neurological disorder caused by mutations in the gene encoding Neurofibromin, a p21Ras GTPase Activating Protein (GAP) [1]. Importantly, NF1 causes learning disabilities and attention deficits [2, 3]. A previous study showed that the learning and memory deficits of a mouse model of NF1 (nf1(+/-)) appear to be caused by excessive p21Ras activity leading to impairments in long-term potentiation (LTP) [4], a cellular mechanism of learning and memory [5-7]. Here, we identify lovastatin as a potent inhibitor of p21Ras/Mitogen Activated Protein Kinase (MAPK) activity [8, 9] in the brain. Lovastatin is a specific inhibitor of three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, used commonly for the treatment of hypercholesterolemia [10]. We report that lovastatin decreased the enhanced brain p21 Ras-MAPK activity of the nf1(+/-) mice, rescued their LTP deficits, and reversed their spatial learning and attention impairments. Therefore, these results demonstrate that lovastatin may prove useful in the treatment of Neurofibromatosis Type 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available